HomeCompareCATV vs JNJ

CATV vs JNJ: Dividend Comparison 2026

CATV yields 1333333.33% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CATV wins by $8.464452558960094e+37M in total portfolio value
10 years
CATV
CATV
● Live price
1333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.464452558960094e+37M
Annual income
$84,632,039,287,279,390,000,000,000,000,000,000,000,000,000.00
Full CATV calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CATV vs JNJ

📍 CATV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCATVJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CATV + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CATV pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CATV
Annual income on $10K today (after 15% tax)
$113,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$71,937,233,394,187,480,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CATV beats the other by $71,937,233,394,187,480,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CATV + JNJ for your $10,000?

CATV: 50%JNJ: 50%
100% JNJ50/50100% CATV
Portfolio after 10yr
$4.232226279480047e+37M
Annual income
$42,316,019,643,639,694,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CATV
No analyst data
Altman Z
-0.2
Piotroski
8/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CATV buys
0
JNJ buys
0
No recent congressional trades found for CATV or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCATVJNJ
Forward yield1333333.33%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$8.464452558960094e+37M$30.3K
Annual income after 10y$84,632,039,287,279,390,000,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$8.464370862343931e+37M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CATV vs JNJ ($10,000, DRIP)

YearCATV PortfolioCATV Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$133,344,033$133,333,333.33$10,592$272.30+$133.33MCATV
2$1,661,750,570,120$1,661,607,892,004.15$11,289$357.73+$1661750.56MCATV
3$19,354,275,468,746,564$19,352,497,395,636,536.00$12,123$472.89+$19354275468.73MCATV
4$210,672,095,393,398,460,000$210,651,386,318,646,900,000.00$13,141$629.86+$210672095393398.47MCATV
5$2,143,168,524,310,646,200,000,000$2,142,943,105,168,575,400,000,000.00$14,408$846.81+$2143168524310646272.00MCATV
6$20,376,287,032,159,666,000,000,000,000$20,373,993,841,838,650,000,000,000,000.00$16,021$1,151.60+$2.0376287032159664e+22MCATV
7$181,056,208,148,895,540,000,000,000,000,000$181,034,405,521,771,130,000,000,000,000,000.00$18,122$1,588.22+$1.8105620814889554e+26MCATV
8$1,503,563,155,360,419,000,000,000,000,000,000,000$1,503,369,425,217,699,500,000,000,000,000,000,000.00$20,930$2,228.20+$1.5035631553604192e+30MCATV
9$11,669,441,422,020,247,000,000,000,000,000,000,000,000$11,667,832,609,444,013,000,000,000,000,000,000,000,000.00$24,792$3,191.91+$1.1669441422020246e+34MCATV
10$84,644,525,589,600,940,000,000,000,000,000,000,000,000,000$84,632,039,287,279,390,000,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$8.464452558960094e+37MCATV

CATV vs JNJ: Complete Analysis 2026

CATVStock

4Cable TV International, Inc. provides specialty solutions to the cable television sector. It offers a suite of products comprising RF to Fiber (RF2F), a proprietary line of coax-to-fiber taps that enables cable operators to reach homes within their franchise authorized area; PowerMiser, a circuitry, which allows a low current 1 GHz amplifier and/or line extender to be constructed with a decrease in current power requirements; RF over Glass (RFoG) signal distribution technology that combines the existing cable TV infrastructure with fiber optics to reach the home; and Node+0 application, which combines the RFoG technology platform with its PowerMiser engineering to take fiber signal. The company also provides SOLAR-CATV that utilizes solar power and helps the operator extend service to areas not presently served without adding power sources; and Dynamically Scalable Return technology, which allows nodes, R-ONU's (RFoG optical network units) to adjust their return bandwidth by changing the channel lineup at the head end, as well as repair, testing, and upgrade services. It markets and sells its products through a network of dealers in the United States and Canada primarily to independent cable TV operators, as well as to multiple system operators. 4Cable TV International, Inc. was incorporated in 2007 and is based in Conway, South Carolina.

Full CATV Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CATV vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CATV vs SCHDCATV vs JEPICATV vs OCATV vs KOCATV vs MAINCATV vs ABBVCATV vs MRKCATV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.